Adriamycin in combination for the treatment of breast cancer.A southwest oncology group study
Open Access
- 27 June 1978
- Vol. 41 (6) , 2078-2083
- https://doi.org/10.1002/1097-0142(197806)41:6<2078::aid-cncr2820410602>3.0.co;2-q
Abstract
Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three‐arm prospective study: adriamycin day 1 plus 5‐FU on day 1 and 8 (AF), adriamycin day 1, plus 5‐FU day 1 and 8, and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5‐FU day 1 and 8, cyclophosphamide day 1 and methotrexate day 1 (AFCM). These courses were repeated every 21 days. The response rate was 44/105(42%) AF, 44/103(43%) AFC and 52/105 (49%) AFCM. The length of response was 22, 33 and 35 weeks, respectively, for AF, AFC and AFCM (P =0.21). The median survival, 64 weeks, was equal in all three limbs. The major toxicity was leukopenia. Twenty‐eight percent developed a WBC of less than 2,000/μ1, which resulted in seven deaths (2.2%).This publication has 6 references indexed in Scilit:
- Adriamycin cardiotoxicity in children.Case reports, literature review, and risk factorsCancer, 1977
- Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.BMJ, 1976
- Combination chemotherapy and adriamycin in patients with advanced breast cancer.A Southwest Oncology Group studyCancer, 1976
- Combination Chemotherapy for Advanced Breast Cancer: Response and Effect on SurvivalAnnals of Internal Medicine, 1976
- Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancerCancer, 1975
- Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma.A southwest cancer chemotherapy study group studyCancer, 1974